Staidson Beijing Biopharma Cash Flow-to-Debt Ratio
Staidson Beijing Biopharma cash flow-to-debt ratio. Staidson Beijing Biopharma (300204) has a Cash Flow-to-Debt Ratio of -0.10x as of September 2025, meaning its operating cash flow of CN¥-39.18 Million could theoretically repay 0% of its total liabilities (CN¥404.22 Million) in one year. Check 300204 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Staidson Beijing Biopharma (2007–2025)
Cash flow-to-debt ratio of Staidson Beijing Biopharma from 2007 to 2025. Historical debt coverage capacity for Staidson Beijing Biopharma across 19 annual periods. Check Staidson Beijing Biopharma (300204) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Staidson Beijing Biopharma Cash Flow-to-Debt Ratio by Year (2007–2025)
Staidson Beijing Biopharma cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Staidson Beijing Biopharma. For the full cash flow conversion analysis, see 300204 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.27x | CN¥-125.68 Million | CN¥459.48 Million | ▼ 0.0% |
| 2024 | -0.27x | CN¥-63.68 Million | CN¥232.85 Million | ▲ +62.5% |
| 2023 | -0.73x | CN¥-227.47 Million | CN¥311.55 Million | ▼ -31.2% |
| 2022 | -0.56x | CN¥-175.60 Million | CN¥315.45 Million | ▲ +5.1% |
| 2021 | -0.59x | CN¥-162.07 Million | CN¥276.25 Million | ▼ -37.6% |
| 2020 | -0.43x | CN¥-114.60 Million | CN¥268.70 Million | ▼ -318.5% |
| 2019 | 0.20x | CN¥44.34 Million | CN¥227.18 Million | ▼ -62.8% |
| 2018 | 0.53x | CN¥165.08 Million | CN¥314.30 Million | ▼ -19.5% |
| 2017 | 0.65x | CN¥273.64 Million | CN¥419.14 Million | ▲ +32.8% |
| 2016 | 0.49x | CN¥212.55 Million | CN¥432.32 Million | ▼ -17.6% |
| 2015 | 0.60x | CN¥231.01 Million | CN¥387.06 Million | ▼ -14.2% |
| 2014 | 0.70x | CN¥206.85 Million | CN¥297.54 Million | ▲ +59.5% |
| 2013 | 0.44x | CN¥111.36 Million | CN¥255.47 Million | ▼ -7.1% |
| 2012 | 0.47x | CN¥90.19 Million | CN¥192.15 Million | ▼ -74.5% |
| 2011 | 1.84x | CN¥87.01 Million | CN¥47.32 Million | ▲ +183.8% |
| 2010 | 0.65x | CN¥63.91 Million | CN¥98.66 Million | ▼ -55.6% |
| 2009 | 1.46x | CN¥42.37 Million | CN¥29.03 Million | ▲ +163.0% |
| 2008 | 0.55x | CN¥16.23 Million | CN¥29.25 Million | ▲ +396.0% |
| 2007 | 0.11x | CN¥5.41 Million | CN¥48.35 Million | — |